

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the Claims**

1. (CURRENTLY AMENDED) A method for treating a patient having a condition affecting at least one layer of skin comprising administering in situ by topical application or injection a physiologically acceptable formulation consisting essentially of at least one hydrolase in an amount of the formulation having a hydrolase concentration selected from the ranges of from about  $1 \times 10^{-5}\%$  w/v to about  $1 \times 10^{-3}\%$  w/v or from about 1% w/v to about 10% w/v and for a duration effective to regulate removal of said layer and treat said condition.

2. (ORIGINAL) The method of claim 1 wherein said layer of skin is selected from the group consisting of an epidermal layer, a dermal layer, a subcutaneous layer, and combinations thereof.

3. CANCELED.

4. (PREVIOUSLY PRESENTED) The method of claim 1 wherein said hydrolase is selected from the group consisting of esterases, glycosidases, proteases, phosphatases, thiolases, phospholipases, amidases, ceramidases, lipases, deaminases, nucleases and combinations thereof.

5. (PREVIOUSLY PRESENTED) The method of claim 1 wherein said hydrolase is selected from the group consisting of trypsin, chymotrypsin, papain, bromelain, dispase, thermolysin, ceramidase, lipase, glycosidase, deoxyribonuclease, ribonuclease and combinations thereof to treat an epidermal layer.

6-7. CANCELED.

8. (ORIGINAL) The method of claim 1 where the condition is selected from the group consisting of neoplasms, pigmentary disorders, infectious disorders, follicular disorders, hyperkeratotic disorders, inflammatory disorders, vascular disorders, photo-aging disorders, deposition disorders, connective tissue disorders, and cutaneous cystic disorders.

9. (PREVIOUSLY PRESENTED) The method of claim 1 wherein the hydrolase is selected from the group consisting of trypsin, chymotrypsin, papain, collagenase, pepsin A, elastase, exopeptidases, aminopeptidases, endopeptidases, bromelain, chymotrypsin C, metridin, trypsin, thrombin, plasmin, enteropeptidase, alpha-lytic endopeptidase, prolyl oligopeptidase, bradykinin, plasma kallikrein, tissue kallikrein, pancreatic elastase, leukocyte elastase, chymase, cerevisin, hypodermin C, endopeptidase La, alpha-renin, leucyl endopeptidase, tryptase, kexin, subtilisin, oryzin, endopeptidase K, thermomycolin, thermitase, endopeptidase So, tissue plasminogen activator, pancreatic endopeptidase E, pancreatic elastase II, urine plasminogen activator, cathepsin B, facain, chymopapain, asclepain, clostripain, streptopain, actinidain, cathepsin L, cathepsin H, calpain, cathepsin T, glycyl endopeptidase, cathepsin S, caricain, ananain, stem bromelain, fruit bromelain, legumain, histolysain, pepsin B, gastricsin, chymosin, cathepsin D, retropain, aspergillopepsin I, aspergillopepsin II, penicillopepsin, rhizopuspepsin, endothiasepsin, mucorpepsin, candidapepsin, saccharopepsin, rhodotorulapepsin, physaropepsin, acrocyllindropepsin, polyporopepsin, pycnoporopepsin, scytalidopepsin A, scytalidopepsin B, xanthomonoapepsin, pseudomonapepsin, cathepsin E, atrolisin, microbial collagenase, leucolysin, interstitial collagenase, neprilysin, matrix metalloproteinases dispace, thermolysin, V8 protease, ribonuclease, deoxyribonuclease and combinations thereof.

10-23. CANCELED.

24. (PREVIOUSLY PRESENTED) A method to treat skin comprising topically applying to an outermost layer of skin a composition consisting essentially of a protease in a biologically acceptable formulation in an amount to selectively regulate removal of at least one epidermal

layer containing a skin condition to thereby treat said skin wherein the formulation has a protease concentration selected from the ranges of from about  $1 \times 10^{-6}\%$  w/v to about  $1 \times 10^{-3}\%$  w/v or from about  $1\%$  w/v to about  $10\%$  w/v.

25. (ORIGINAL) The method of claim 24 wherein said protease is selected from the group consisting of trypsin, papain, bromelain, dispase, thermolysin, and combinations thereof.

26-29. CANCELED.

30. (PREVIOUSLY PRESENTED) A method to target skin treatment of an affected area comprising providing to said affected area by topical application or injection a composition consisting essentially of at least one hydrolase in an amount and formulation effective to selectively regulate skin removal in said affected area wherein the composition has a hydrolase concentration selected from the ranges of from about  $1 \times 10^{-5}\%$  w/v to about  $1 \times 10^{-3}\%$  w/v or from about  $1\%$  w/v to about  $10\%$  w/v.

31. (ORIGINAL) The method of claim 30 wherein said affected area is selected from the group consisting of epidermis, dermis, subcutaneous layer, and combinations thereof.

32-33. CANCELED.

34. (CURRENTLY AMENDED) A method for treating a condition affecting skin comprising applying by topical application or injection a composition to the affected skin, the composition containing at least one hydrolase at a concentration selective for regulating depth of skin treatment wherein the concentration of the hydrolase is selected from the ranges of from about  $1 \times 10^{-5}\%$  w/v to about  $1 \times 10^{-3}\%$  w/v or from about  $1\%$  w/v to about  $10\%$  w/v and applied to an area selective for regulating a radial surface of skin treatment.

35. (PREVIOUSLY PRESENTED)      The method of claim 34 wherein the hydrolase is a protease.

36. CANCELED.

37. (ORIGINAL) The method of claim 34 wherein the composition comprises a protease and is topically applied.

38. (ORIGINAL) The method of claim 34 wherein the composition is applied one time.

39. (PREVIOUSLY PRESENTED)      The method of claim 34 wherein the hydrolase is a protease to treat an epidermal layer.

40. (PREVIOUSLY PRESENTED)      The method of claim 34 wherein a relatively short duration of exposure and a relatively low hydrolase concentration is used to treat a condition affecting an epidermal layer.

41-42. CANCELED.

43. (PREVIOUSLY PRESENTED)      The method of claim 8 where the condition is seborrheic keratosis.

44-63. CANCELED.